This collaboration will streamline the ordering and delivery of molecular tests, enabling healthcare providers to electronically order and track Prolaris and MyRisk tests, with results delivered ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...

(RTTNews) - Myriad Genetics, Inc. (MYGN), a genetic testing and precision medicine company, on Wednesday announced its groundbreaking study results on the Prequel Prenatal Screen with AMPLIFY ...

Opening plenary session features latest fetal fraction amplification researchSALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...

Emergen Research Logo The DNA Testing market is expected to grow from an estimated USD 12.51 billion in 2024 to USD 81.82 billion in 2033, ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.COWbVb-l.js ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The gene panel market is expected to grow at 20.02 % CAGR from 2023 to 2030. It is expected to reach above USD 13.2 billion by 2030 from USD 3.02 billion in 2023. List of the Top Key Players of the ...